CLIMATE-FORUM-RY
28.5.2019 08:51:08 CEST | Business Wire | Press release
The greenhouse effect, according to the IPCC, is due to the longwave absorption of 156 Wm-2 by greenhouse gases and partly by clouds. This absorption flux should be able to reradiate back to the Earth 346 Wm-2 , which is impossible according to the energy conservation laws of physics. The overall effect of greenhouse gases is about 50% lower than the prevailing theory.
Other energy sources beside longwave radiation absorption are shortwave radiation absorption by the greenhouse gases and latent and sensible heating. Together, these four energy sources perfectly explain the reradiation flux by the atmosphere on the Earth’s surface. The total absorption contribution of 2.4 °C by carbon dioxide (CO2 ) of 400 ppm means that the carbon dioxide warming effect of the IPCC’s calculations is about 200% too high.
“The portions of individual contributors are: water 45.6%, latent heating 30.8%, sensible heating 8.2%, carbon dioxide 7.3%, ozone 6.1%, clouds 0.9%, methane & nitrogen oxide 0.7% and aerosols 0.3%. The cloud effect is minimal, and it differs from other earlier studies (19% and 39%) because these studies do not consider the reduction of solar insolation by clouds,” said Ollila.
The reproduction of the radiative forcing by CO2 gave a 41.6% lower value for 560 ppm than the same of the IPCC. The radiative forcing values are transformed into warming values by the climate sensitivity parameter (CSP). The CSP value of the IPCC is 0.5 K/(Wm-2 ), which includes so-called positive water feedback, and which doubles the warming effects of greenhouse gases. According to this study, the CSP value is 0.27 K/(Wm-2 ). The direct humidity and temperature observations confirm that there is no positive water feedback in the atmosphere,” said Ollila.
“The warming effect of CO2 , according to the radiative forcing equation and the CSP value of this study, can be nicely fitted into the overall greenhouse effect of CO2 , but it is not the case in the simple model of the IPCC,” said Ollila.
Journal Reference :
Ollila, Antero. Challenging the greenhouse effect specification and the climate sensitivity of the IPCC . Physical Science International Journal, 22(2): 1-19, 2019. http://www.journalpsij.com/index.php/PSIJ/article/view/30127/56520
View source version on businesswire.com: https://www.businesswire.com/news/home/20190527005324/en/
Contact:
Climate Forum ry Dr. Antero Ollila, Adjunct Associate Professor, Emeritus tel. +358442437365 aveollila@yahoo.com Link
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom